消费风起，布局医药消费正当时 20251111 摘要 沃伍生物股价表现良好，方盛制药和佐力药业股价接近历史新高，具备 投资机会，这些公司拥有收入、利润和现金流，是优质投资标的。 医疗服务行业受 DRG 政策和消费环境影响业绩较弱，但预计 2026 年将 改善。供给端收缩，民营医院扩张受阻，并购或新增大医院或改善表观 数据。 眼科领域关注爱尔、华夏和普瑞，预计 2026 年一季度屈光业务将释放 业绩。白内障筛查明年有望好转，当前股价底部具备投资价值。 通策医疗紫金港总院和义乌浙中总院开业，红云分院进展放缓，亏损减 少。预计 2026 年收入和利润增速将提升，公司处于拐点位置。 固生堂去年快速扩张，今年新增多家分院并进入天津市场，收购深圳天 元医院。三季度利润增速高于收入增速，全年业绩预期超 30%，估值偏 低。 海吉亚受医保影响较大，但目前处于底部，公司持续增持。明年无锡、 常熟新医院开设及重庆、西安医院增长有望修复表观数据。 流感相关企业如国邦、普洛药业和联邦制药产能利用率大幅提升，满产 满销。若流感持续爆发，可能出现短缺和涨价，四季度及明年一季度业 绩有望显著增长。 我们坚定看好医药创新，包括创新药及其产业 ...

据媒体报道，今年7月，华润系旗下多家上市公司发布公告称，将与上海复星医药产业发展有限公司、成都国企等共同投资设立华润医药（成都）创新投 资基金合伙企业（有限合伙），将聚焦医药健康主责主业和战略新兴产业。 | | 草公司 都在用的商业查询工具 | 查老板 宣关系 草风险 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | 了解除罪人意欲之 | 华润(成都)医药产业股权投资基金台伙企业(有限台 8 | 天服 下 | | 商务合作 企业级产品。 | | | | 基本信息 283 | 法律诉讼 | 经营风险 | 经营信息 | 公司发展 | 知识产权 | | 历史信息(V) | | 合伙人信息 12 3 ● | 品股权结构 | | 合伙人类型, 认数金额, | 2持股比例, | ○点击进行搜索 | ■ 合用 | 2天眼查 | | 序号 | 合伙人名称 | | 出资比例: | 认缴出资额(万元); | 认缴出资日期: | 间接持股比例 | 关联产品机构 | | 1 | 成都高新策源启航股权投资基金合伙企业(有限合伙) 国际 私募量能 | | ...

Core Insights - Recently, China Resources (Chengdu) Pharmaceutical Industry Equity Investment Fund Partnership (Limited Partnership) was established with a capital contribution of 1 billion yuan [1] - The fund's business scope includes venture capital, specifically limited to investments in unlisted companies [1] - The fund is jointly funded by several companies, including Fosun Pharma, Dong-E E-Jiao, Boya Bio, China Resources Double Crane, and Jiangzhong Pharmaceutical [1] Company Contributions - Fosun Pharma's wholly-owned subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., is a key contributor to the fund [1] - Other contributors include Dong-E E-Jiao, Boya Bio, China Resources Double Crane, and Jiangzhong Pharmaceutical, indicating a collaborative investment approach among major players in the pharmaceutical industry [1] Investment Focus - The fund is specifically focused on venture investments, which suggests a strategic interest in supporting early-stage pharmaceutical companies [1] - The emphasis on unlisted companies may provide opportunities for high-growth potential investments within the pharmaceutical sector [1]

| | 早,河 都在用的商业查询工具 | 查老板 查风险 | | | | | | --- | --- | --- | --- | --- | --- | --- | | | 国家上加拿球中国发言少了书籍 | 华润(成都)医药产业股权投资基金合伙企业(有限合 8 | 天眼一下 | ■ 应用 ▼ | 商务合作 企业级产品、 ■ 开通会 | | | 基本信息 283 | 法律诉讼 | 经营风险 | 经营信息 | 公司发展 | 知识产权 | | | 工商信息 历史工商信息0 | | | | | | | | 企业名称 | 华润(成都)医药产业股权投资基金合伙企业(有限合伙) | | | | | | | 执行事务合伙人 | 华润医药科技(成都)合伙企业 家庭 医药 | 登记状态 7 | 存续 | | 天眼评分 2 | 97 9 | | | (有限合伙) | 成立日期 | 2025-11-07 | | | | | 统一社会信用代码 2 | 91510100MAK126UR31 | 出资额 | 100000万人民币 | | 立創 | | | 工商注册号 | 510109202136044 | 纳税人识别号 2 | 91510 ...

Core Insights - Recently, China Resources (Chengdu) Pharmaceutical Industry Equity Investment Fund Partnership (Limited Partnership) was established with a capital contribution of 1 billion RMB, focusing on venture capital [1] Group 1: Fund Establishment - The fund's executive partner is China Resources Pharmaceutical Technology (Chengdu) Partnership (Limited Partnership) [1] - The fund is co-funded by Chengdu Major Industrialization Project Phase II Equity Investment Fund Co., Ltd., Boya Bio (300294), Dong-E E-Jiao (000423), China Resources Double Crane (600062), and Jiangzhong Pharmaceutical (600750) [1] Group 2: Strategic Focus - In July, several listed companies under China Resources announced plans to jointly invest in the establishment of China Resources Pharmaceutical (Chengdu) Innovation Investment Fund Partnership (Limited Partnership) with Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. and Chengdu state-owned enterprises [1] - The focus of this new fund will be on the pharmaceutical health main business and strategic emerging industries [1]

出租车电子计价器属于国家实行强制检定的计量器具，其计量准确与否直接关系乘客切身利益。 在天津市市场监管委查处出租车计价器作弊系列案中，26辆出租车的电子计价器装有作弊装置，且 其中16台电子计价器超期未检定；26辆出租车的司机利用作弊装置增加计价里程，多收乘车费。天津市 市场监管委依据计量法有关规定，没收相关出租车司机涉案电子计价器及附带作弊装置共计26套、罚款 合计3.1万元，并将非法安装作弊装置的相关当事人移交公安机关。 生产销售侵犯注册商标专用权的商品，不仅侵犯商标权利人利益，也损害公平竞争的市场秩序。 出租车电子计价器作弊、生产销售假冒"亚朵星球"枕头、非法改装电动自行车进行销售……市场监 管总局5日公布2025"守护消费"铁拳行动第二批典型案例。 在上海市奉贤区市场监管局查处上海茗步信息科技有限公司侵害消费者权益案中，当事人在销售话 费、外卖会员、影视平台月卡等权益包产品过程中，要求消费者开通会员时勾选同意增值权益服务协 议，其中含有"用户购买会员服务后……系统将在会员到期前自动续费"等条款，并在自动续费前未通过 任何方式提请消费者注意。市场监管部门依据消费者权益保护法等有关法规，给予当事人警告并罚 ...

新华社北京11月5日电题：市场监管总局公布"守护消费"铁拳行动第二批典型案例 新华社记者赵文君 出租车电子计价器作弊、生产销售假冒"亚朵星球"枕头、非法改装电动自行车进行销售……市场监 管总局5日公布2025"守护消费"铁拳行动第二批典型案例。 出租车电子计价器属于国家实行强制检定的计量器具，其计量准确与否直接关系乘客切身利益。 在天津市市场监管委查处出租车计价器作弊系列案中，26辆出租车的电子计价器装有作弊装置，且 其中16台电子计价器超期未检定；26辆出租车的司机利用作弊装置增加计价里程，多收乘车费。天津市 市场监管委依据计量法有关规定，没收相关出租车司机涉案电子计价器及附带作弊装置共计26套、罚款 合计3.1万元，并将非法安装作弊装置的相关当事人移交公安机关。 生产销售侵犯注册商标专用权的商品，不仅侵犯商标权利人利益，也损害公平竞争的市场秩序。 在江苏省南通市通州区市场监管局查处生产销售侵犯他人注册商标专用权的枕头案中，现场查获印 有"亚朵星球"等注册商标的枕头543件、各类包装盒2206件、印有商标的产品吊牌17245件，经商标权利 人鉴定，均为侵权产品。当事人在未取得商标权利人授权的情况下，擅自生产 ...

Core Viewpoint - The article discusses the establishment of significant investment funds by China Resources Double Crane and China Resources Pharmaceutical, focusing on synthetic biology and innovative pharmaceuticals, indicating a strategic shift towards high-growth sectors in the biomanufacturing industry [2][3]. Investment Fund Establishment - China Resources Double Crane and China Resources Pharmaceutical announced the formation of a 500 million RMB fund, with a commitment of 123 million RMB from the group, representing 24.6% of the total fund [2]. - China Resources Double Crane also established the "China Resources Double Crane Industry Fund," committing up to 83 million RMB, approximately 16.6% of the total fund, aimed at optimizing strategic layout in synthetic biology [3]. Collaboration and Partnerships - The funds involve collaboration with local governments and multiple investors, including 11 limited partners (LPs) such as various China Resources entities and Chengdu local government funds, collectively forming a 1 billion RMB investment fund [3][4]. - The partnership includes significant contributions from local government funds and private enterprises, showcasing a collaborative approach to investment in the biomanufacturing sector [4]. Strategic Focus on Synthetic Biology - China Resources Double Crane has previously invested 502 million RMB to acquire a 50.11% stake in Shenzhou Biology, enhancing its capabilities in the biomanufacturing field [5]. - The establishment of a synthetic biology research institute in 2023 indicates a commitment to developing a comprehensive R&D, pilot testing, and industrialization system, focusing on industrial enzymes and microorganisms [5]. Research and Development Initiatives - The company has developed seven technology platforms in synthetic biology, with over ten ongoing projects, leveraging expertise from seasoned scientists with experience in major corporations [5].

除运送航天员外，神舟飞船还肩负着运送高价值、高时效性载荷等职责，能够更好地为我们的太空家园"添砖加瓦"。 至此，我国2025年载人航天发射任务圆满收官。这次任务是工程进入空间站应用与发展阶段的第6次载人飞行任务，也是工程立项实施以来的第37次发射任 务。截至目前，我国已有28名航天员、44人次进入太空执行飞行任务。 10月31日23时44分，我国成功发射神舟二十一号载人飞船，2025年载人航天发射任务也圆满收官。这次任务是长征系列运载火箭的第604次飞行、神舟飞船 的第21次飞行，也是华润江中旗下参灵草第12次伴随神舟飞船开启太空征程。 神舟二十一号成功发射 10月31日23时44分，搭载神舟二十一号载人飞船的长征二号F遥二十一运载火箭在酒泉卫星发射中心点火发射，约10分钟后，飞船与火箭成功分离，进入预 定轨道，航天员乘组状态良好，发射取得圆满成功。这次任务是长征系列运载火箭的第604次飞行、神舟飞船的第21次飞行。 神舟二十一号载人飞船入轨后，于11月1日3时22分，成功对接于空间站天和核心舱前向端口，整个对接过程历时约3.5小时，创造了神舟飞船与空间站交会 对接的最快纪录。 成功发射的同时，神舟飞船搭载的 ...

Core Insights - The traditional Chinese medicine sector experienced a rise of 1.47% on October 31, with Zhongsheng Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3954.79, down 0.81%, while the Shenzhen Component Index closed at 13378.21, down 1.14% [1] Stock Performance - Zhongsheng Pharmaceutical (002317) closed at 19.32, up 10.02% with a trading volume of 772,500 shares and a transaction value of 1.454 billion [1] - Weikang Pharmaceutical (300878) closed at 24.91, up 8.59% with a trading volume of 79,700 shares and a transaction value of 195 million [1] - Darentang (600329) closed at 45.13, up 7.02% with a trading volume of 231,800 shares and a transaction value of 1.059 billion [1] - ST Xiangxue (300147) closed at 10.13, up 6.41% with a trading volume of 219,400 shares and a transaction value of 220 million [1] - Zhendong Pharmaceutical (300158) closed at 6.98, up 5.44% with a trading volume of 611,600 shares and a transaction value of 421 million [1] Capital Flow - The traditional Chinese medicine sector saw a net inflow of 524 million from main funds, while retail funds experienced a net outflow of 69.05 million [2] - Main funds showed significant net inflow into Zhongsheng Pharmaceutical at 318 million, while retail funds had a net outflow of 161 million [3] - Darentang had a main fund net inflow of 84.64 million, with retail funds showing a net outflow of 88.84 million [3]